Ford has a unique background. He has over forty years of experience
in the health care field. He has spent his entire career in
the pharmaceutical industry. He started out after an NIH post-doctoral
fellowship at Stanford University, as a medicinal chemist
at CIBA Pharmaceuticals Inc in Summit NJ. Where he synthesized
novel compounds in his own laboratory. In this laboratory
he completed one of the first syntheses of prostaglandin E1
(Alprostadil®), for which he was awarded a D.Sc. degree.
He subsequently became responsible for all Medicinal Chemistry
in the US for the successor company CIBA-Geigy. He then became
Executive Director reporting to the VP for R&D in the
US. In this capacity he was also responsible for Drug Metabolism,
and a Chemical Development operation which provided material
for the IND toxicology studies and Phase I studies in man.
Dr. Ford left CIBA-Geigy in 1981 to
enter Washington University School of Medicine in St Louis.
He obtained an MD degree in 1985 and trained in internal medicine
at Jewish Hospital in St. Louis. He boarded in Internal Medicine and Clinical Pharmacology. He joined the Clinical Pharmacology
department at Squibb in 1988, as Associate Director. He subsequently
became Executive Director of Clinical Pharmacology in the
successor company Bristol-Myers Squibb, and was responsible
for the early clinical development plans for the Cardiovascular,
Metabolic, Dermatological, Urological and Neuroscience programs.
He played an active role in the interfaces with Regulatory
Affairs and Clinical Research.
Dr. Ford is a Fellow of the American
College of Physicians and the American College of Clinical
Pharmacology. He is on the Editorial Board of the Journal of Clinical Pharmacology. He is Clinical
Associate Professor of Medicine at the Robert Wood Johnson
School of Medicine, UMDNJ, New Brunswick, NJ. In 2005 he received
the volunteer Faculty Teaching Award from the Department of